Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis.

Ann-Christin PecherKatharina Renate AchWichard VogelJoerg Christoph Henes

Published in: Rheumatology (Oxford, England) (2022)

Our data demonstrate that a reduced cyclophosphamide mobilization regimen seems to be feasible. Risk factors for poor mobilization might be low bodyweight, prior rituximab therapy and cardiac involvement.

Keyphrases

stem cell transplantation
systemic sclerosis
high dose
interstitial lung disease
low dose
diffuse large b cell lymphoma
bone marrow
cell therapy
electronic health record
stem cells
hodgkin lymphoma
chronic lymphocytic leukemia
smoking cessation